You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

FOSRENOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Fosrenol, and what generic alternatives are available?

Fosrenol is a drug marketed by Takeda Pharms Usa and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has ninety-one patent family members in thirty-one countries.

The generic ingredient in FOSRENOL is lanthanum carbonate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fosrenol

A generic version of FOSRENOL was approved as lanthanum carbonate by NATCO PHARMA LTD on August 11th, 2017.

  Try a Trial

Drug patent expirations by year for FOSRENOL
Drug Prices for FOSRENOL

See drug prices for FOSRENOL

Recent Clinical Trials for FOSRENOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical Universtity of LodzPhase 4
Medical University of LodzPhase 4
Universitair Ziekenhuis BrusselPhase 3

See all FOSRENOL clinical trials

Pharmacology for FOSRENOL
Drug ClassPhosphate Binder
Mechanism of ActionPhosphate Chelating Activity
Paragraph IV (Patent) Challenges for FOSRENOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FOSRENOL Oral Powder lanthanum carbonate 750 mg and 1000 mg 204734 1 2015-11-25
FOSRENOL Chewable Tablet lanthanum carbonate 500 mg, 750 mg and 1000 mg 021468 3 2008-10-27

US Patents and Regulatory Information for FOSRENOL

FOSRENOL is protected by four US patents.

Patents protecting FOSRENOL

Stabilized lanthanum carbonate compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

Pharmaceutical formulation comprising lanthanum compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Capsule and powder formulations containing lanthanum compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Capsule and powder formulations containing lanthanum compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-004 Nov 23, 2005 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FOSRENOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-001 Oct 26, 2004 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 ⤷  Try a Trial ⤷  Try a Trial
Takeda Pharms Usa FOSRENOL lanthanum carbonate TABLET, CHEWABLE;ORAL 021468-003 Nov 23, 2005 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for FOSRENOL

See the table below for patents covering FOSRENOL around the world.

Country Patent Number Title Estimated Expiration
Hungary E024906 ⤷  Try a Trial
Norway 20082538 ⤷  Try a Trial
Eurasian Patent Organization 000270 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ВЫБРАННЫЕ ГИДРАТЫ КАРБОНАТА ЛАНТАНА (PHARMACEUTICAL COMPOSITION CONTAINING SELECTED LANTHANUM CARBONATE HYDRATES) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FOSRENOL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0817639 PA2008005,C0817639 Lithuania ⤷  Try a Trial PRODUCT NAME: LANTANO KARBONATO HIDRATAS; NAT. REGISTRATION NO/DATE: LT/1/07/0776/001-021 20071003; FIRST REGISTRATION: 17192, 2004-03-19 ; 18466, 2004-03-19; 21073, 2004-10-19; 21074 20041029
0817639 PA2008005 Lithuania ⤷  Try a Trial PRODCUT NAME: LANTANO KARBONATO HIDRATAS; NAT. REG. DATE/NO: LT/1/07/0776/001-021; FIRST REG. DATE: 20040319
0817639 SPC/GB06/036 United Kingdom ⤷  Try a Trial SPC/GB06/036: 20061027
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.